Characterization of microbiome and metabolite analyses in patients with metabolic associated fatty liver disease and type II diabetes mellitus

Yang, Qiuping; Zhang, Leisheng; Li, Qian; Gu, Man Bock; Qu, Qing; Yang, Xinglong; Yi, Qinghua; Gu, Kunli; Kuang, Linli; Mei, Hao; Xu, Jing; Yang, Hongju

doi:10.1186/s12866-022-02526-w

Cited by 11 publications

(11 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 38 studies 11–21,33,35,36,38–41,44–46,48,49,51–53,56,58–62,64–66,68–71,74,75,78,79,82,84 provided data for α‐diversity (Table 1), which was then assessed using eight indices, namely richness/evenness (Shannon [ n = 37, 3186 cases, and 3990 controls]）, Chao1 [ n = 16, 1002 cases, and 1824 controls], Simpson [ n = 12, 488 cases, and 419 controls]), estimates of richness (observed species [ n = 10, 836 cases, and 813 controls], richness [ n = 7, 791 cases, and 1354 controls], faith phylogenetic diversity [PD, n = 6, 761 cases, and 1936 controls], evenness [Pielou, n = 6, 552 cases, and 185 controls]), and abundance coverage estimator (ACE; n = 4, 64 cases and 73 controls).…”

Section: Resultsmentioning

confidence: 99%

“…A total of 38 studies [11][12][13][14][15][16][17][18][19][20][21]33,35,36,[38][39][40][41][44][45][46]48,49,[51][52][53]56,[58][59][60][61][62][64][65][66][68][69][70][71]74,75,78,79,82,84 provided data for α-diversity (Table 1), which was then assessed using eight indices, namely richness/evenness (Shannon T A B L E 2 Total analysis, stratified analysis, and sensitivity analysis among alpha diversity.…”

Section: α-Diversitymentioning

confidence: 99%

“…A total of 47 studies [11][12][13][14][15][16][17][18][19][20][21][33][34][35][36][38][39][40][41][43][44][45]48,49,51,52,55,[57][58][59][60][61][62][63][64][65][66]68,69,73,75,[77][78][79][81][82][83] reported data for β-diversity (Table 1), 25 studies reported results by using the weighted or unweighted Unifrac method to calculate distance, 17 studies used the Bray-Curtis method, and few studies used various methods (Figure 3 and Appendix S7). Significant differences in β-diversity were reported by over 75% (37/47) of the included studies, and the remain...…”

Section: β-Diversitymentioning

confidence: 99%

See 2 more Smart Citations

Composition of gut microbiota and non‐alcoholic fatty liver disease: A systematic review and meta‐analysis

Su,

Chen,

Liu

et al. 2023

Obesity Reviews

View full text Add to dashboard Cite

SummaryThe present systematic review and meta‐analysis aimed to summarize the associations between gut microbiota composition and non‐alcoholic fatty liver disease. To compare the differences between individuals with or without NAFLD, the standardized mean difference and 95% confidence interval were computed for each α‐diversity index and relative abundance of gut microbes. The β‐diversity indices were summarized in a qualitative manner. A total of 54 studies with 8894 participants were included. Overall, patients with NAFLD had moderate reduction in α‐diversity indices including Shannon (SMD = −0.36, 95% CI = [−0.53, −0.19], p < 0.001) and Chao 1 (SMD = −0.42, 95% CI = [−0.68, −0.17], p = 0.001), but no significant differences were found for Simpson, observed species, phylogenetic diversity, richness, abundance‐based coverage estimator, and evenness (p ranged from 0.081 to 0.953). Over 75% of the included studies reported significant differences in β‐diversity. Although there was substantial interstudy heterogeneity, especially for analyses at the phylum, class, and family levels, the majority of the included studies showed alterations in the depletion of anti‐inflammatory microbes (i.e., Ruminococcaceae and Coprococcus) and the enrichment of proinflammatory microbes (i.e., Fusobacterium and Escherichia) in patients with NAFLD. Perturbations in gut microbiota were associated with NAFLD, commonly reflected by a reduction in beneficial species and an increase in the pathogenic species.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: α-Diversitymentioning

confidence: 99%

Section: β-Diversitymentioning

confidence: 99%

See 1 more Smart Citation

Composition of gut microbiota and non‐alcoholic fatty liver disease: A systematic review and meta‐analysis

Su,

Chen,

Liu

et al. 2023

Obesity Reviews

View full text Add to dashboard Cite

show abstract

“…The performances of the aforementioned blood-based biomarkers and scores for NASH or fibrotic NASH is summarized in Table 2. Some recent studies have focused on 'omic markers' [48][49][50] to corroborate the findings of raised production of lipidomic, 51,52 proteomic, metabolomics, 53 and microbiome markers 54 in patients with NAFLD. Nevertheless, these require further validation; and while attempting to improve accuracy, the key to obtaining an effective non-invasive biomarker to diagnose at-risk or fibrotic NASH in clinical practice is for it to be simple, low cost, and easily available.…”

Section: Non-invasive Assessment For Nashmentioning

confidence: 91%

Non-invasive assessment of metabolic dysfunction–associated fatty liver disease

Kumar

Skantha

Chan

2022

Therapeutic Advances in Endocrinology

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) affects an estimated one-quarter of the global adult population and has become one of the leading causes of end-stage liver disease and hepatocellular carcinoma with increased liver-related and overall morbidity and mortality. The new term, metabolic dysfunction–associated fatty liver disease (MAFLD), has a set of positive diagnostic criteria and has been shown to have better clinical utility, but it has yet to be universally adopted. This review addresses the non-invasive tests for MAFLD and is based mostly on studies on NAFLD patients, as the MAFLD term is relatively new and there are limited studies on non-invasive tests based on this new term, while a large body of research work on non-invasive tests has accumulated in the literature for NAFLD. This review focuses on blood-based biomarkers and scores for the assessment of hepatic steatosis, non-alcoholic steatohepatitis (NASH), and fibrosis, and two of the most widely studied imaging biomarkers, namely vibration-controlled transient elastography and magnetic resonance imaging. Fibrotic NASH has become a diagnostic target of interest and novel serum biomarkers and scores incorporating imaging biomarker for diagnosis of fibrotic NASH are emerging. Nonetheless, the degree of liver fibrosis remains the key predictor of liver-related morbidity and mortality in patients with MAFLD. A multitude of non-invasive biomarkers and scores have been studied for the detection of liver fibrosis, including use of sequential non-invasive tests for risk stratification of advanced liver fibrosis. In addition, this review will explore the utility of the non-invasive tests for prognostication and for monitoring of treatment response.

show abstract

“…Yang et al compared the gut microbiota of 20 patients with MAFLD, 20 patients with MAFLD and T2DM, and 19 healthy control subjects, using 16S rRNA sequencing from stool samples [ 25 ]. Bacteroidetes , Firmicutes , and Proteobacteria were the most abundant phyla in case groups (MAFLD and MAFLD + T2DM, respectively) vs. healthy control subjects ( p < 0.05).…”

Section: Gut Microbiota Changes In Mafld Patientsmentioning

confidence: 99%

Metabolic-Dysfunction-Associated Fatty Liver Disease and Gut Microbiota: From Fatty Liver to Dysmetabolic Syndrome

et al. 2023

View full text Add to dashboard Cite

Metabolic-dysfunction-associated fatty liver disease (MAFLD) is the recent nomenclature designation that associates the condition of non-alcoholic fatty liver disease (NAFLD) with metabolic dysfunction. Its diagnosis has been debated in the recent period and is generally associated with a diagnosis of steatosis and at least one pathologic condition among overweight/obesity, type 2 diabetes mellitus, and metabolic dysregulation. Its pathogenesis is defined by a “multiple-hit” model and is associated with alteration or dysbiosis of the gut microbiota. The pathogenic role of dysbiosis of the gut microbiota has been investigated in many diseases, including obesity, type 2 diabetes mellitus, and NAFLD. However, only a few works correlate it with MAFLD, although common pathogenetic links to these diseases are suspected. This review underlines the most recurrent changes in the gut microbiota of patients with MAFLD, while also evidencing possible pathogenetic links.

show abstract

Characterization of microbiome and metabolite analyses in patients with metabolic associated fatty liver disease and type II diabetes mellitus

Cited by 11 publications

References 51 publications

Composition of gut microbiota and non‐alcoholic fatty liver disease: A systematic review and meta‐analysis

Composition of gut microbiota and non‐alcoholic fatty liver disease: A systematic review and meta‐analysis

Non-invasive assessment of metabolic dysfunction–associated fatty liver disease

Metabolic-Dysfunction-Associated Fatty Liver Disease and Gut Microbiota: From Fatty Liver to Dysmetabolic Syndrome

Contact Info

Product

Resources

About